Enterprise Value
2.054B
Cash
431.2M
Avg Qtr Burn
-20.63M
Short % of Float
19.56%
Insider Ownership
4.45%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NVL-520 Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Phase 1/2 Data readout | |
NVL-655 Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 1/2 Data readout |